SwingTrade Member Forum

[10 bagger]

PYNGF.. Cross Post...

I continue to keep buying.. This stock is CHEAP..hank

Pyng Medical Corp.

03/04/11 11:01 AM EST Buy 3888 PYNGF Executed @ $0.303 Details | Edit
03/04/11 11:01 AM EST Buy 5000 PYNGF Executed @ $0.303 Details | Edit
03/04/11 10:59 AM EST Buy 388 PYNGF Executed @ $0.2987 Details | Edit
03/04/11 10:59 AM EST Buy 3500 PYNGF Executed @ $0.2987 Details | Edit
03/04/11 10:59 AM EST Buy 5000 PYNGF Executed @ $0.299 Details | Edit
03/02/11 2:10 PM EST Buy 7888 PYNGF Executed @ $0.299 Details | Edit
03/02/11 2:09 PM EST Buy 5000 PYNGF Executed @ $0.299 Details | Edit

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=60586495&txt2find=pyngf

03/01/11 11:35 AM EST Buy 17388 PYNGF Executed @ $0.2618 Details | Edit


-------------------------------------

PYNGF.. Pyng Medical Corp.

03/01/11 11:35 AM EST Buy 17388 PYNGF Executed @ $0.2618 Details | Edit

Completed an order of 18,888 today.. Nice little company with earnings and a decent balance sheet.. Has just raised capitol from a non-brokered private placement basis, 3,000,000 common shares at $0.20 per share for net proceeds of $600,000 to a single investor, MDR Specialty Distribution Corporation of Williamsburg, Virginia ("MDR"). MDR is a wholesale medical supplier distributor with revenues in excess of US$50,000,000 per year... hank

Reports First Quarter Fiscal 2011 Results

Company Symbols: OTC-PINK:PYNGF, TorontoVE:PYT


VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 23, 2011) - Pyng Medical Corp. (TSX VENTURE:PYT) today announced its financial and operating results for the three months ended December 31, 2010. All amounts are in Canadian dollars unless stated otherwise.

The Company continued revenue growth realized in the fourth quarter of last year and reported another record quarter with strong shipments of the flagship product FAST1. Total sales of $2,041,737 were recorded for the first quarter of fiscal 2011, up 29% from $1,585,684 from the same quarter last year. Gross margin for the quarter ended December 31, 2010 amounted to $1,398,349, an increase of $265,443 from $1,132,906 reported a year ago. Gross margin as a percentage of sales decreased from 71% to 69%, which was mainly due to the continuing appreciation of Canadian dollar against the U.S. dollar (more than 93% of sales are in U.S. dollars). Total operating expenses were $990,995, down to 49% of sales compared to $1,102,189 or 69% of sales for the same quarter last year. This was primarily due to the lower labor costs, travel costs, and interest expenses incurred during the quarter.

The Company also reported net income of $407,354 for this quarter, equal to earnings of $0.03 per share diluted, compared to $30,717 or $0.003 per share diluted for the same quarter of last year. Earnings before interest, depreciation, amortization and taxes ("EBITDA") from continuing operations increased to $575,207, 27% of the sales, compared with the EBITDA of $151,835, or 10% of sales a year ago.

As of December 31, 2010, the Company had a cash balance of $1,382,457 and working capital of $1,730,028, representing an increase of $1,099,464 and $968, 773 respectively, compared to similar amounts as of September 30, 2010. Strong operating results and the private placement financing that closed in December 2010 were primary contributors to improvements seen in cash and working capital.

Full audited financial results for fiscal year ended September 30, 2010 are available on SEDAR at www.sedar.com.

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", " projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FOR FURTHER INFORMATION PLEASE CONTACT:

Pyng Medical Corp.
George Dorin
Chief Financial Officer
[phone] ext. 219
www.pyng.com
===================================================
Pyng Medical Provides Update on FASTx(R)

Dow Jones and Company, Inc. - Feb 10 at 10:58 NONE

Company Symbols: OTC-PINK:PYNGF, TorontoVE:PYT


VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 10, 2011) - Pyng Medical (TSX VENTURE:PYT) announced that it has completed a root-cause analysis on FASTx(R) in follow-up to reported insertion failures in a handful of early military training environments. From this analysis Pyng has validated that there are times where lateral motion can bend the insertion needle (stylet). This has not been observed in the unconscious patient or in cadaver validation; however it has been seen with live/conscious healthy patients in training settings. Pyng is now pursuing several options to mitigate root-cause and anticipates choosing a final solution within the next several months.

Mark Hodge, President and Chief Executive Officer for Pyng, commented; " Shortening the FASTx(R) redevelopment timeline, while at the same time bringing back an even more robust product to market, is Pyng Medical's number one priority. The company is by no means "accepting a long timeline" and will engage all necessary resources to minimize the duration of the process."

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", " projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FOR FURTHER INFORMATION PLEASE CONTACT:

Pyng Medical Corp.
Mark F. Hodge
Chief Executive Officer
1-800-349-7964 (x208)
www.pyng.com

======================================================
Pyng Medical Announces It Has Closed a $600,000 Private Placement

Dow Jones and Company, Inc. - Dec 30 at 09:30 NONE

Company Symbols: OTC-PINK:PYNGF, TorontoVE:PYT


VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 30, 2010) - Pyng Medical Corp. ("Pyng") (TSX VENTURE:PYT) announced today that all necessary regulatory and other required approvals have been obtained and on December 29, 2010 it issued, on a non-brokered private placement basis, 3,000,000 common shares at $0.20 per share for net proceeds of $600,000 to a single investor, MDR Specialty Distribution Corporation of Williamsburg, Virginia ("MDR"). MDR is a wholesale medical supplier distributor with revenues in excess of US$50,000,000 per year. One of the principals of MDR, Mr. Herbert A. Toms 3rd, was appointed to the Pyng board of directors upon closing of the placement. Mr. Toms, one of the founders of MDR, has been in the medical device supply business for over 12 years. Mr. Toms brings extensive experience and knowledge to Pyng regarding both domestic and international medical device warehousing and distribution.

There were no finder's fees payable in connection with the placement. All securities issued in connection with the placement are subject to a statutory hold period of four months plus a day from December 29, 2010, the date of issuance, in accordance with applicable securities legislation.

The proceeds of the placement will be used for general working capital and to pursue international sales opportunities.

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", " projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FOR FURTHER INFORMATION PLEASE CONTACT:

Pyng Medical Corp.
George Dorin
Chief Financial Officer & Corporate Secretary
604-303-7964
604-303-7987 (FAX)
[e-mail]
www.pyng.com

========================================================
Pyng Medical Achieves Record Sales for October

Dow Jones & Company, Inc. - Nov 22 at 13:18 NONE

Company Symbols: OTC-PINK:PYNGF, TorontoVE:PYT


VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 22, 2010) - Pyng Medical Corp. (TSX VENTURE:PYT) today announced record sales in the month of October, 2010 for its FAST1(R) Sternal Intraosseous Device. Nadine Gaston, Pyng Vice President of Global Sales and Marketing, noted that "Almost 8,000 FAST1(R) devices were sold in October, far surpassing results in that month from previous fiscal years. The positive momentum we had developed in our record setting 4th Quarter of Fiscal Year 2010 (July, August, September) has continued into the new Fiscal Year." Ms. Gaston also remarked, "I believe Pyng's education efforts regarding the unique clinical benefits of sternal IO are beginning to have an impact, particularly in the worldwide military market."

Mark Hodge, Pyng President and Chief Executive Officer, commented, "It's extremely gratifying to see our customers respond to Pyng's recent efforts in the creation of mutually beneficial partnerships that enhance patient care. I believe that Pyng Medical is well positioned for future growth if we continue to keep our priorities focused on patients, distributors, and business plan execution."

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", " projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FOR FURTHER INFORMATION PLEASE CONTACT:

Pyng Medical Corp.
Mark F. Hodge
Chief Executive Officer
1-800-349-7964 (x208)
www.pyng.com
==========================================================

Pyng Medical Initiates Voluntary Recall of the FASTx(TM)

Dow Jones & Company, Inc. - Nov 16 at 10:25 NONE

Company Symbols: OTC-PINK:PYNGF, TorontoVE:PYT


VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 16, 2010) - Pyng Medical (TSX VENTURE:PYT) announced today that it has initiated a voluntary recall of the FASTx(TM) Sternal Intraosseous Device. Pyng received feedback regarding inconsistent performance of FASTx(TM) in several early training sessions that were conducted and, as a result, recalled the first 400 devices shipped to distributors. Pyng has discontinued shipment of future devices until it can evaluate these happenings and determine root cause.

"This voluntary recall was initiated because it is simply the right thing to do when there is any question regarding the performance of a medical device," said Mark Hodge, President and CEO of Pyng, in a statement related to the company's action. "The Pyng technical team is working rapidly to analyze these events and determine a course of action. We will ensure that the FASTx(TM) Sternal Intraosseous Device is performing as we expect it to perform and will provide ongoing updates."

The revolutionary clinical benefits available through utilization of the FAST1(R) Sternal Intraosseous Device will not be impacted by this voluntary action. During this period of FASTx(TM) evaluation, the FAST1(R) continues to ship to customers desiring the benefits of sternal IO, anatomical land marking, automatic depth control, and secure placement.

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", " projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FOR FURTHER INFORMATION PLEASE CONTACT:

Pyng Medical Corp.
Mark F. Hodge
Chief Executive Officer
1-800-349-7964 (x208)
www.pyng.com
========================================================
Pyng Medical Corp.: Simpler and Faster IO Hits the USA With the FASTx(TM) Sternal Intraosseous Device

Dow Jones & Company, Inc. - Sep 14 at 17:17 NONE

Company Symbols: OTC-PINK:PYNGF, TorontoVE:PYT


VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 14, 2010) - Pyng Medical Corp. (TSX VENTURE:PYT) - Gaining vascular access just got faster and simpler with the FASTx(TM) Sternal Intraosseous device now available in the United States. The all-in-one FASTx(TM) is light, compact and requires no additional tools or pre-use incisions to provide fluids, medication, and blood quickly and easily. The built-in anatomical land marking allows placement even in challenging conditions. While automatic depth-control eliminates the guesswork around how deep to go providing for clear and confident vascular access, the new target foot, now integrated into the device, provides for stability and aids in proper alignment to deploy simply. "It's these benefits that the FASTx(TM) provides which allows for important new vascular access options for hospital systems, EMS services, and Federal/Military customers, at a time when IO has increasingly become the recommended standard of care, that has resulted in strong early customer preference," according to Nadine Gaston, Global Vice President of Sales and Marketing.

Sara Clark MS, RN, CCRN-CSC, Critical Care Educator at the Denver Veterans Medical Center, is one of the first US customers to purchase the FASTx(TM) in the weeks since US 510(k) clearance. Ms. Clark shares, "I'm excited about bringing the new technology that FASTx(TM) has to offer to the Denver Veterans Medical Center, not only because it will benefit the veterans we are caring for in our facility, from World War II veterans, to veterans presenting from Iraq and Afghanistan, but also because I'll have the opportunity to reach veterans from all across the United States." After evaluating alternative technologies, the Denver VA team decided to standardize on the FASTx(TM). According to Ms. Clark, "thanks to FASTx(TM), nurses will be able to provide early treatment, prevent costly bloodstream infections related to central line insertions in sub- optimal conditions, and provide the deserving care to our veterans who sacrifice life and limb."

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.

For more information please visit us on our website at www.pyng.com.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", " projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FOR FURTHER INFORMATION PLEASE CONTACT:

Pyng Medical Corp.
Nadine Gaston
VP Global Sales & Marketing
[e-mail]
www.pyng.com
=====================================================